PubRank

M A Villalona-Calero

Author PubWeight™ 20.38‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002 2.42
2 Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol 1999 1.56
3 Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002 1.51
4 Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells. Oncogene 2001 1.30
5 Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. Br J Cancer 2005 1.11
6 Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer Chemother Pharmacol 2012 1.03
7 Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol 1998 0.97
8 A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2004 0.96
9 Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 1999 0.95
10 Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol 2001 0.91
11 Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. Cancer Chemother Pharmacol 2008 0.84
12 A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors. Invest New Drugs 2005 0.84
13 Extragonadal abdominal germ cell cancers. Am J Clin Oncol 1992 0.81
14 An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochem Biophys Res Commun 2009 0.80
15 Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. J Clin Oncol 2000 0.79
16 RT-PCR heteroduplex analysis permits differentiation of transgene and host gene expression in a transgenic animal model. Biotechniques 2002 0.78
17 Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. J Clin Oncol 2000 0.78
18 Alternative dosing schedules for irinotecan. Oncology (Williston Park) 1998 0.77
19 A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors. Clin Cancer Res 1999 0.76
20 Secondary acute myelogenous leukemia in children with Latin-American ancestry. J Clin Oncol 1993 0.75
21 Acute progranulocytic leukemia (APL): possible in vivo differentiation by granulocyte colony-stimulating factor (G-CSF) Leukemia 1993 0.75